ストックスクリーナーアプリを入手
8.10
8.00%
0.60
アフターアワーズ：
8.30
0.20
+2.47%
前日終値:
$7.50
開ける：
$7.51
24時間の取引高:
1.11M
Relative Volume:
0.88
時価総額：
$553.86M
収益：
-
当期純損益:
$-297.11M
株価収益率:
-1.8493
EPS:
-4.38
ネットキャッシュフロー:
$-216.95M
1週間 パフォーマンス:
+3.58%
1か月 パフォーマンス:
-9.70%
6か月 パフォーマンス:
-20.74%
1年 パフォーマンス:
-11.96%
1日の値動き範囲:
$7.395
$8.31
1週間の範囲:
$7.03
$8.31
52週間の値動き範囲:
$6.065
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
名前
Phathom Pharmaceuticals Inc
セクター
電話
(877) 742-8466
住所
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
PHAT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
8.10 | 553.86M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.65 | 105.75B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.68 | 78.76B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
632.04 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.50 | 31.28B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.77 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-03 | 開始されました | Stifel | Buy |
| 2024-01-05 | 繰り返されました | Needham | Buy |
| 2023-08-09 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 開始されました | Craig Hallum | Buy |
| 2022-10-21 | 開始されました | Jefferies | Buy |
| 2022-05-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2021-05-12 | アップグレード | Goldman | Sell → Neutral |
| 2021-02-17 | 開始されました | BMO Capital Markets | Outperform |
| 2021-02-02 | 開始されました | Guggenheim | Buy |
| 2020-06-26 | ダウングレード | Goldman | Neutral → Sell |
| 2019-11-20 | 開始されました | Evercore ISI | Outperform |
| 2019-11-19 | 開始されました | Goldman | Neutral |
| 2019-11-19 | 開始されました | Jefferies | Buy |
| 2019-11-19 | 開始されました | Needham | Buy |
すべてを表示
Phathom Pharmaceuticals Inc (PHAT) 最新ニュース
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading 7.1% HigherWhat's Next? - MarketBeat
State Street Corp Raises Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
State Street Corp Increases Stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Phathom Pharmaceuticals CFO Molly Henderson sells $10,328 in stock By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals CFO Molly Henderson sells $10,328 in stock - Investing.com India
Phathom Pharmaceuticals COO sells shares for $8,944 - Investing.com India
Phathom Pharmaceuticals COO sells shares for $8,944 By Investing.com - Investing.com South Africa
Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells 1,291 Shares of Stock - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 2%Here's Why - MarketBeat
Phathom Pharmaceuticals Inc (PHAT) Recovers 28.94% From Low: Are We There Yet? - Stocks Register
FDA Tracker: FDA Hands Out Atopic Dermatitis Approvals to Galderma, Organon - BioSpace
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up After Insider Buying Activity - Defense World
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Frank Karbe buys $99,083 in Phathom Pharmaceuticals stock By Investing.com - Investing.com Australia
Frank Karbe buys $99,083 in Phathom Pharmaceuticals stock - Investing.com India
Phathom Pharmaceuticals director Asit Parikh buys $81,248 in stock By Investing.com - Investing.com South Africa
How To Trade (PHAT) - Stock Traders Daily
Insider Buying: Asit Parikh Acquires 10,000 Shares of Phathom Ph - GuruFocus.com
Frank Karbe Increases Stake in Phathom Pharmaceuticals Inc (PHAT) - GuruFocus.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up on Insider Buying Activity - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director Acquires $99,125.00 in Stock - MarketBeat
Phathom Pharmaceuticals director Asit Parikh buys $81,248 in stock - Investing.com
Phathom Pharmaceuticals’ (PHAT) “Buy” Rating Reiterated at HC Wainwright - Defense World
Insider Sellers Might Regret Selling Phathom Pharmaceuticals Shares at a Lower Price Than Current Market Value - Simply Wall St
Charles Schwab Investment Management Inc. Purchases 6,990 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals Submits Citizen Petition to FDA for Correction of Orange Book Listings for VOQUEZNA Tablets - Defense World
Phathom Pharma shares stay Buy rated on extended vonoprazan exclusivity to 2032 - Investing.com Canada
Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)? - MSN
Phathom Pharmaceuticals (NASDAQ:PHAT) Receives "Buy" Rating from HC Wainwright - MarketBeat
Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable (NASDAQ:PHAT) - Seeking Alpha
Phathom Pharmaceuticals seeks FDA clarity on drug exclusivity - Investing.com
Phathom Pharmaceuticals seeks FDA clarity on drug exclusivity By Investing.com - Investing.com UK
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets - The Manila Times
Phathom Pharmaceuticals Submits Citizen Petition to FDA - GlobeNewswire
Fmr LLC Boosts Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround - MSN
Point72 Asset Management L.P. Takes Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Wasatch Advisors LP Buys Shares of 246,942 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 3.5%Should You Sell? - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Short Interest Update - MarketBeat
Eagle Asset Management Inc. Increases Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
(PHAT) Technical Pivots with Risk Controls - Stock Traders Daily
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap DownTime to Sell? - MarketBeat
Jennison Associates LLC Has $106.06 Million Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know - MSN
Phathom Pharmaceuticals - The Healthcare Technology Report.
Phathom Pharmaceuticals Inc (PHAT) 財務データ
収益
当期純利益
現金流量
EPS
0.50%
1.47%
大文字化:
|
ボリューム (24 時間):